Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giorgio Bellati

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Artificial Organs|January 8, 2014
Development of high-efficiency molecular adsorbent recirculating system: preliminary reportRoberto Marangoni, Giorgio Bellati, Alessandro Castelli, et al.
Journal of Medical Virology|March 12, 2003
Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapyAlessandro R Zanetti, Luisa Romanò, Maurizia Brunetto, et al.
Internal and Emergency Medicine|November 23, 2006
Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled studyGianpiero Benetti, Mauro Borzio, Giuliano Ramella, et al.
Antiviral Therapy|September 6, 2008
Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosisLuigi Roffi, Guido Colloredo, Pietro Pioltelli, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Artificial Organs|January 8, 2014
Development of high-efficiency molecular adsorbent recirculating system: preliminary reportRoberto Marangoni, Giorgio Bellati, Alessandro Castelli, et al.
Journal of Medical Virology|March 12, 2003
Total HCV core antigen assay: a new marker of hepatitis C viremia for monitoring the progress of therapyAlessandro R Zanetti, Luisa Romanò, Maurizia Brunetto, et al.
Internal and Emergency Medicine|November 23, 2006
Daily dose of interferon alpha-2b and ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection: a randomised controlled studyGianpiero Benetti, Mauro Borzio, Giuliano Ramella, et al.
Antiviral Therapy|September 6, 2008
Pegylated interferon-alpha2b plus ribavirin: an efficacious and well-tolerated treatment regimen for patients with hepatitis C virus related histologically proven cirrhosisLuigi Roffi, Guido Colloredo, Pietro Pioltelli, et al.
Pageof 1